Role of biologics in severe food allergy.
Journal
Current opinion in allergy and clinical immunology
ISSN: 1473-6322
Titre abrégé: Curr Opin Allergy Clin Immunol
Pays: United States
ID NLM: 100936359
Informations de publication
Date de publication:
28 Mar 2024
28 Mar 2024
Historique:
medline:
28
3
2024
pubmed:
28
3
2024
entrez:
27
3
2024
Statut:
aheadofprint
Résumé
This review examine the dynamic landscape of food allergy treatment within the context of emerging biologics. Our purpose is to comprehensively evaluate the potential benefits, challenges, and transformative impact associated with the utilization of biologics in comparison to conventional therapeutic modalities. This document synthesizes recent scientific investigations to various biologics, such as omalizumab, ligelizumab, dupilumab, and tezepelumab, providing a nuanced understanding of their roles in oral immunotherapy, rapid desensitization, and overall food allergy management. Recent studies and clinical trials highlight the impact of anti-IgE treatment on food allergies, revealing critical findings such as dose-related efficacy, facilitation of rapid desensitization in peanut allergies, and the sustained positive outcomes observed in individuals with multifood allergies. The use of biologics presents a groundbreaking approach in the treatment of food allergies. The multifaceted action of these agents, along with their potential to overcome the challenges associated with traditional therapies, marks a significant advancement. Despite the persisting challenges of economic constraints and the need for further safety studies, biologics offer a promising avenue for improving the quality of life for individuals with food allergies. Ongoing research and collaborative efforts are imperative to fully realize the transformative potential inherent in these emerging therapeutic frontiers.
Identifiants
pubmed: 38538153
doi: 10.1097/ACI.0000000000000978
pii: 00130832-990000000-00113
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Gupta RS, Warren CM, Smith BM, et al. Prevalence and severity of food allergies among US adults. JAMA Netw Open 2019; 2:e185630.
Grabenhenrich L, Trendelenburg V, Bellach J, et al. Frequency of food allergy in school-aged children in eight European countries—the EuroPrevall-iFAAM birth cohort. Allergy 2020; 75:2294–2308.
Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J 2020; 13:100472.
Simons FER, Ardusso LR, Bilò MB, et al. International consensus on (ICON) anaphylaxis. World Allergy Organ J 2014; 7:9.
Westwell-Roper C, To S, Andjelic G, et al. Food-allergy-specific anxiety and distress in parents of children with food allergy: a systematic review. Pediatr Allergy Immunol 2022; 33:e13695.
Arasi S, Nurmatov U, Dunn-Galvin A, et al. WAO consensus on DEfinition of Food Allergy SEverity (DEFASE). World Allergy Organ J 2023; 16:100753.
Alvaro-Lozano M, Akdis CA, Akdis M, et al. EAACI allergen immunotherapy user's guide. Pediatr Allergy Immunol 2020; 31: (Suppl 25): 1–101.
Nurmatov U, Dhami S, Arasi S, et al. Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. Allergy 2017; 72:1133–1147.
Pajno GB, Fernandez-Rivas M, Arasi S, et al. EAACI guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy 2018; 73:799–815.
Arasi S, Ebisawa M, Eigenmann P, et al. Editorial comment on “Oral immunotherapy as a curative treatment for food-allergic preschool children: current evidence and potential underlying mechanisms”. Pediatr Allergy Immunol 2024; 35: e14071.
Dinardo G, Fierro V, Del Giudice MM, et al. Food-labeling issues for severe food-allergic consumers. Curr Opin Allergy Clin Immunol 2023; 23:233–238.
Chinthrajah RS, Cao S, Dunham T, et al. Oral immunotherapy for peanut allergy: the pro argument. World Allergy Organ J 2020; 13:100455.
O’B Hourihane J, Beyer K, Abbas A, et al. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. Lancet Child Adolesc Heal 2020; 4:728–739.
Bird JA, Spergel JM, Jones SM, et al. Efficacy and Safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trial. J Allergy Clin Immunol Pract 2018; 6:476–485. e3.
Jones SM, Kim EH, Nadeau KC, et al. Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. Lancet 2022; 399:359–371.
Vickery BP, Berglund JP, Burk CM, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. J Allergy Clin Immunol 2017; 139:173–181. e8.
Pouessel G, Lezmi G. Oral immunotherapy for food allergy: translation from studies to clinical practice? World Allergy Organ J 2023; 16:100747.
Chinthrajah RS, Purington N, Andorf S, et al. Development of a tool predicting severity of allergic reaction during peanut challenge. Ann Allergy Asthma Immunol 2018; 121:69–76. e2.
Fleischer DM, Greenhawt M, Sussman G, et al. Effect of epicutaneous immunotherapy vs placebo on reaction to peanut protein ingestion among children with peanut allergy: the PEPITES Randomized Clinical Trial. JAMA 2019; 321:946–955.
Chu DK, Freitag T, Marrin A, et al. Peanut oral immunotherapy with or without H1 and H2 antihistamine premedication for peanut allergy (PISCES): a placebo-controlled randomized clinical trial. J allergy Clin Immunol Pract 2022; 10:2386–2394.
Ciaccio C, Goldsobel AB, Anagnostou A, et al. Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials. Ann Allergy Asthma Immunol 2022; 129:758–768. e4.
Sindher SB, Fiocchi A, Zuberbier T, et al. The role of biologics in the treatment of food allergy. J Allergy Clin Immunol Pract 2023; 12:562–568.
Bousquet J, Humbert M, Gibson PG, et al. Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. J Allergy Clin Immunol Pract 2021; 9:2702–2714.
Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy 2020; 75:1023–1042.
Indolfi C, Dinardo G, Klain A, et al. Time effect of dupilumab to treat severe uncontrolled asthma in adolescents: a pilot study. Allergol Immunopathol (Madr) 2023; 51:12–18.
Dinardo G, Indolfi C, Klain A, et al. Treatment of severe asthma: fast action of dupilumab in the pediatric setting. Minerva Pediatr 2023; 75:312–313.
Agache I, Song Y, Alonso-Coello P, et al. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines. Allergy 2021; 76:2337–2353.
Sindher SB, Barshow S, Tirumalasetty J, et al. The role of biologics in pediatric food allergy and eosinophilic gastrointestinal disorders. J Allergy Clin Immunol 2023; 151:595–606.
Zuberbier T, Wood RA, Bindslev-Jensen C, et al. Omalizumab in IgE-mediated food allergy: a systematic review and meta-analysis. J allergy Clin Immunol Pract 2023; 11:1134–1146.
Fiocchi A, Artesani MC, Riccardi C, et al. Impact of omalizumab on food allergy in patients treated for asthma: a real-life study. J allergy Clin Immunol Pract 2019; 7:1901–1909. e5.
Azzano P, Paquin M, Langlois A, et al. Determinants of omalizumab dose-related efficacy in oral immunotherapy: evidence from a cohort of 181 patients. J Allergy Clin Immunol 2021; 147:233–243.
MacGinnitie AJ, Rachid R, Gragg H, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol 2017; 139:873–881. e8.
Brandström J, Vetander M, Sundqvist AC, et al. Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents. Clin Exp Allergy 2019; 49:1328–1341.
Wood RA, Kim JS, Lindblad R, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy. J Allergy Clin Immunol 2016; 137:1103–1110. e11.
Chinthrajah RS, Purington N, Andorf S, et al. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2019; 394:1437–1449.
Bégin P, Dominguez T, Wilson SP, et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy Asthma Clin Immunol 2014; 10:7.
Andorf S, Purington N, Block WM, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol 2018; 3:85–94.
Andorf S, Purington N, Kumar D, et al. A phase 2 randomized controlled multisite study using omalizumab-facilitated rapid desensitization to test continued vs discontinued dosing in multifood allergic individuals. EClinicalMedicine 2019; 7:27–38.
Langlois A, Lavergne MH, Leroux H, et al. Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multifood oral immunotherapy. Allergy Asthma Clin Immunol 2020; 16:25.
Sindher S, Kumar D, Purington N, et al. A phase 2 study of multi oral immunotherapy in multi food allergic patients to test immune markers after minimum maintenance dose using xolair. J Allergy Clin Immunol 2020; 145:AB135.
Arasi S, Mennini M, Cafarotti A, et al. Omalizumab as monotherapy for food allergy. Curr Opin Allergy Clin Immunol 2021; 21:286–291.
Dinardo G, Cafarotti A, Galletta F, et al. Omalizumab in severe asthma and food allergies with IgE levels >1500 kU/L: two-year evaluation. Pediatr Allergy Immunol 2023; 34:e14057.
Sampson HA, Leung DYM, Burks AW, et al. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2011; 127:1309–1310. e1.
Wood RA, Chinthrajah RS, Rudman Spergel AK, et al. Protocol design and synopsis: Omalizumab as Monotherapy and as Adjunct Therapy to Multiallergen OIT in Children and Adults with Food Allergy (OUtMATCH). J Allergy Clin Immunol Glob 2022; 1:225–232.
Groetch M, Mudd K, Woch M, et al. Retail food equivalents for post-oral immunotherapy dosing in the omalizumab as monotherapy and as adjunct therapy to multi-allergen Oral Immunotherapy in Food-Allergic Children and Adults (OUtMATCH) Clinical Trial. J Allergy Clin Immunol Pract 2023; 11:572–580. e2.
Wood RA, Chinthrajah RS, Eggel A, et al. The rationale for development of ligelizumab in food allergy. World Allergy Organ J 2022; 15:100690.
Spekhorst LS, van der Rijst LP, de Graaf M, et al. Dupilumab has a profound effect on specific-IgE levels of several food allergens in atopic dermatitis patients. Allergy 2023; 78:875–878.
Chinthrajah S, Cao S, Liu C, et al. Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy. JCI insight 2019; 4:131347.
Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N Engl J Med 2021; 385:1656–1668.
Corren J, Ambrose CS, Sałapa K, et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma and perennial allergy. J allergy Clin Immunol Pract 2021; 9:4334–4342. e6.